Abiopharma

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

Zynex Reports Second Quarter 2025 Financial Results

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Nephros Q2 2025 Financial Results Conference Call

New Form 4 - RETRACTABLE TECHNOLOGIES INC Filed: 2025-07-31 AccNo: 0001415889-25-020712 Size: 5 KB

New Form SCHEDULE 13G - IMMUNIC, INC. Filed: 2025-07-31 AccNo: 0001085146-25-004384 Size: 8 KB

New Form 10-Q - PACIFIC HEALTH CARE ORGANIZATION INC Filed: 2025-07-31 AccNo: 0001185185-25-000876 Size: 3 MB

New Form 144 - Gryphon Digital Mining, Inc. Filed: 2025-07-31 AccNo: 0001973379-25-000207 Size: 4 KB

New Form 144 - Gryphon Digital Mining, Inc. Filed: 2025-07-31 AccNo: 0001973379-25-000206 Size: 4 KB

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.